Hoping to improve on the success of Atripla - and extend the patent life of its lucrative HIV franchise - Gilead Sciences Inc. partnered with Tibotec Pharmaceuticals Ltd. to develop another three-in-one pill combining its Truvada with Tibotec's late-stage non-nucleoside reverse transcriptase inhibitor TMC278. (BioWorld Today) Read More
